Navigation Links
New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders

ization estimates that 170 million individuals have chronic HCV infection, with 3 to 4 million new infections each year.

Therapy for HCV currently employs a drug combination approach, which is anticipated to continue in the future. The current standard of care for treatment-naive chronic hepatitis C is pegylated interferon combined with ribavirin, which fails to provide a satisfactory outcome for approximately 50% of patients infected with HCV genotype 1 (the most prevalent genotype in North America). In addition, these drugs can cause significant side effects that limit tolerance to therapy, or a frequent lack of sustained treatment response.

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs primarily in the area of infectious diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C infections (Phase II and preclinical), the prevention of catheter-related infections (Phase III) and the treatment of dermatological diseases (Phase II). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Additional information can be found at www.migenix.com.

    "Signed"

    James M. DeMesa, M.D.

    President & CEO


    FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, and forward looking information within the meaning of applicable securities laws in Canada, (collectively referred to as "forward-looking statements"). Statements, other than statements of historical fact, are forward-looking statements and include, without limitation, statements regarding our strategy, future operations, timing and completion of clinical trials, prospects, plans and objectives of management. The words "anticipate
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:2/27/2015)... LONDON , February 27, 2015 ... - new study showing you trends, R&D progress, and ... medicine heading? What are the commercial prospects for ... shows you potential revenues and other trends to 2025, ... ,s report lets you assess regenerative medicine : ...
(Date:2/27/2015)... - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), ... for its first quarter ended December 31, 2014. ... 2014, revenue was $1,336,685. Operating expenses were $1,063,393.  Net ... share.  Covalon,s President and CEO, ... the significant progress we have made over the past ...
(Date:2/27/2015)... , February 27, 2015 ... bahnbrechendes Überwachungssystem für kongestive Herzinsuffizienz (CHF) in ...     ... ein neuartiges Herzüberwachungssystem für Patienten mit kongestiver ... dass sie ein Finanzierungsvorhaben über 5 Mio. ...
Breaking Medicine Technology:Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2
... 28, 2010 /PRNewswire-Asia/ -- Chindex International, Inc. ("Chindex") ... American provider of Western healthcare products and services ... Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"), a ... medicine and devices in China, today announced the ...
... that new in-demand ResearchInChina reports on China industries ... Beer Industry Report, 2009-2010 . The report discusses development of ... in China. The study provides data on sales volume and ... product features and marketing strategies. China ...
Cached Medicine Technology:Chindex and Fosun Pharma Form Joint Venture 2Chindex and Fosun Pharma Form Joint Venture 3Chindex and Fosun Pharma Form Joint Venture 4Chindex and Fosun Pharma Form Joint Venture 5Topical China Industries Research Reports Published at MarketPublishers.com 2
(Date:2/27/2015)... Hispanics develop alcoholic liver disease (ALD), ... 12 years earlier than Whites/Caucasians or African Americans, according ... , While previous research indicated that Hispanics tend to ... study -- published online in the journal Alcoholism: Clinical ... first to pinpoint racial and ethnic disparities in the ...
(Date:2/27/2015)... Beverly Hills, CA (PRWEB) February 27, 2015 ... was in the air for those suffering from Sjögren’s ... had been discovered by researchers at the University of ... the next phase of research was to develop a ... to precisely detect the presence of new autoantibodies. Researchers ...
(Date:2/27/2015)... Clinovo, a leading provider of cloud-based eClinical ... (EDC) at the CALBIO2015 conference taking place ... 3rd at Booth # 141. , ClinCapture ... edit-check builder allowing Clinical Trials Managers to create CRFs ... any programming experience. Clinovo’s new pricing model offers a ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 In honor of American ... Primary Care (CPC) South office, is offering tips on how to ... of death, but that doesn't mean people have to accept it ... some risk factors — such as family history, sex or age ... , Dr. Scott has six helpful tips to improve heart ...
(Date:2/27/2015)... February 27, 2015 The federal court ... that allege use of the statin medication can increase ... issued a new order pertaining discovery in the cases ... Liebhard LLP comments. The Order, which was issued in ... February 25th, directs the parties to schedule certain witness ...
Breaking Medicine News(10 mins):Health News:UC Davis Study Finds Hispanics Develop Alcoholic Liver Disease at Younger Ages than Caucasians or African Americans 2Health News:Breakthrough Blood Test for Early Detection of Sjögren’s Syndrome Now Available 2Health News:Clinovo to Demo Its Self-Service, Cloud-Based EDC Solution at CALBIO2015 on March 2nd and 3rd, 2015 2Health News:Center for Primary Care Celebrates American Heart Month 2Health News:Center for Primary Care Celebrates American Heart Month 3Health News:Center for Primary Care Celebrates American Heart Month 4Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 2Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 3
... , ST. PAUL, Minn., Dec. 10 /PRNewswire-USNewswire/ -- ... their 6th annual blood drive event with the Minnesota Vikings ... at the St. Paul Donor Center (I-94 and Hwy. 280), ... cheerleaders scheduled to arrive around 2 PM. All presenting ...
... ... announces that, after a national search, the Board of Trustees of Abington Health voted to ... ... H. Durham, chairman, Board of Trustees of Abington Health and Abington Memorial Hospital, announces that, ...
... , ARLINGTON, Va., Dec. 10 Americans ... but are highly aware of the risks of not receiving care, ... Mental Illness (NAMI). , See full survey results at ... people of diverse communities. , Though depression is common and highly ...
... , Helps PSI, DFID and USAID highlight progress in ... 10 Emmy Award winning actress and PSI (Population Services ... and individuals who have contributed to the substantial decline in ... six years Zimbabwe has seen a dramatic reduction in the ...
... the emissions leaving a car tailpipe or factory smokestack affect ... the atmosphere. But until now, scientists have struggled to know ... once they leave their source, leading to models for predicting ... accurate. A major collaborative effort of more than ...
... Pennsylvania School of Medicine have developed a new model of ... molecule called Src kinase is activated in human skin-cancer samples. ... are activated in human squamous cell carcinomas of the skin. ... gene Fyn, a member of Src family of proteins, in ...
Cached Medicine News:Health News:Minnesota Vikings Team With Memorial Blood Centers Again for Annual Blood Drive 2Health News:Abington Health Announces New President and CEO 2Health News:Abington Health Announces New President and CEO 3Health News:Depression Survey: Implications for Diverse Communities 2Health News:Emmy Award Winning Actress Debra Messing Visits Zimbabwe 2Health News:Emmy Award Winning Actress Debra Messing Visits Zimbabwe 3Health News:New approach to emissions makes climate and air quality models more accurate, major study finds 2Health News:New approach to emissions makes climate and air quality models more accurate, major study finds 3Health News:New model of skin cancer provides insights on second-most common type of cancer 2
Ideal for abdominal and back procedures....
Female High Waist Briefs...
Provides upper and lower arm support. Extends to the lower arm and across the shoulders. Has two columns of hook & eye closure for added adjustability....
Short-Sleeve Bolero for targeted compression in the upper arms, back and shoulder areas. Plush-shielded hook and eye front closure for comfort and convenient application....
Medicine Products: